

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SUN PHARMACEUTICAL INDUSTRIES LTD</u> (Last) (First) (Middle) <u>SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E)</u> (Street) <u>MUMBAI MAHARASHTRA K7 400063</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>scPharmaceuticals Inc. [SCPH]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/21/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/21/2017		C		1,810,536	A	(1)	1,810,536	I	By Sun Pharmaceutical Industries, Inc. (2)
Common Stock	11/21/2017		P		357,143	A	\$14	357,143	I	By Sun Pharma (Netherlands) B.V. (3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series B Preferred Stock	(4)	11/21/2017		C		13,000,000		(4)	(4)	Common Stock	1,810,536 (4)	\$0.00	0	I	By Sun Pharmaceutical Industries, Inc. (2)

1. Name and Address of Reporting Person*
SUN PHARMACEUTICAL INDUSTRIES LTD
 (Last) (First) (Middle)
SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E)
 (Street)
MUMBAI MAHARASHTRA K7 400063
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SHANGHVI DILIP S
 (Last) (First) (Middle)
SUN HOUSE, 201 B/1, WESTERN EXPRESS HIGHWAY, GOREGAON (E)
 (Street)
MUMBAI MAHARASHTRA K7 400063
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
[Sun Pharma \(Netherlands\) B.V.](#)

(Last) (First) (Middle)
[POLARISAVENUE 87](#)

(Street)
[HOOFDDORP P7 2132 JH](#)

(City) (State) (Zip)

1. Name and Address of Reporting Person*
[Sun Pharmaceutical Industries, Inc.](#)

(Last) (First) (Middle)
[270 PROSPECT PLAINS ROAD](#)

(Street)
[CRANBURY NJ 08512](#)

(City) (State) (Zip)

Explanation of Responses:

1. Represents the total number of shares of Common Stock received by Sun Pharmaceutical Industries, Inc. upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
2. Sun Pharmaceutical Industries Limited ("Sun Pharma") directly and indirectly owns all shares of Sun Pharmaceutical Industries, Inc., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharmaceutical Industries, Inc. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein.
3. Sun Pharma is the sole shareholder of Sun Pharma (Netherlands) B.V., which is the registered owner of the securities. Sun Pharma may be deemed to beneficially own all of the shares of the Issuer held by Sun Pharma (Netherlands) B.V. Dilip S. Shanghvi is the controlling shareholder of Sun Pharma. Sun Pharma and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein.
4. All series of the Issuer's Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017. The Series B Preferred Stock had no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

[/s/ Dilip S. Shanghvi](#) [11/24/2017](#)

[/s/ Jeremy Barr, Attorney-in-Fact](#)
[\(on behalf of Sun Pharmaceutical](#) [11/24/2017](#)
[Industries Limited\)](#)

[/s/ Jeremy Barr, Attorney-in-Fact](#)
[\(on behalf of Sun Pharmaceutical](#) [11/24/2017](#)
[Industries, Inc.\)](#)

[/s/ Jeremy Barr, Attorney-in-Fact](#)
[\(on behalf of Sun Pharma](#) [11/24/2017](#)
[\(Netherlands\) B.V.\)](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeremy Barr and Evgeniya Berezkina, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in connection with the undersigned's beneficial ownership of, or participation in a group with respect to, securities beneficially owned, directly or indirectly, of scPharmaceuticals Inc., a Delaware corporation (the "Company"), forms and documents related specifically to Section 13 and Section 16 of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act"), and any joint filing agreement in connection with the foregoing;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such forms and documents related specifically to Section 13 and Section 16 of the Exchange Act, complete and execute any amendment or amendments thereto, and timely file such form and documents with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and

(3) take any other lawful action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in any such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. All lawful acts done by the attorney-in-fact in this regard shall be deemed to have been done by the undersigned. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 or Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file forms and documents related specifically to Section 13 and Section 16 of the Exchange Act with respect to the undersigned's holdings of and transactions in securities issued by the Company, or for a period of one (1) year, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact, whichever is earlier.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of November, 2017.

Sun Pharmaceutical Industries Ltd.

By: /s/ Sailesh T. Desai

Name: Sailesh T. Desai
Title: Director

Sun Pharmaceutical Industries, Inc.

By: /s/ Abhay Gandhi

Name: Abhay Gandhi
Title: CEO - North America

Sun Pharma (Netherlands) B.V.

By: /s/ Prashant Salva

Name: Prashant Salva
Title: Director